By Tony Fong

NEW YORK (GenomeWeb News) – With two recent deals, Life Technologies is positioning itself to capitalize on what could be the next big market opportunity in the life sciences.

During the past two weeks the Carlsbad, Calif.-based company has completed two deals giving it a seat at the synthetic biology table — a field with a market size that has been projected to reach $2.4 billion by 2013.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.